BioSpace News Archive

ITM Isotope Technologies Munich SE today announced that the company will present an overview of genetic tumor and blood profiling in its ongoing phase III clinical trial COMPOSE (NCT04919226 ) in a poster presentation at the 20th Annual European Neuroendocrine Tumor Society (ENETS) Conference held from March 22-24, 2023 in Vienna, Austria, and virtually.

Synthego Corp. announced the launch of its service partner ecosystem, CRISPR Discovery Partners, designed to accelerate drug discovery by providing a seamless research workflow from CRISPR editing to phenotypic data and downstream services.

A bioprocess engineering company called OmniBRx Biotechnologies Private Limited has secured $5 million Series-A funding from SIDBI Ventures and others.

Sana Biotechnology, Inc., a company focused on creating and delivering engineered cells as medicines, reported financial results and business highlights for the fourth quarter and year ended December 31, 2022.

Rani Therapeutics Holdings, Inc. announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2022 on Wednesday, March 22 after the close of trading.

Avail announced today that Daniel Hawkins, CEO of Avail Medsystems, will participate in a keynote panel session at Life Science Intelligence’s (LSI) Emerging MedTech Summit USA 2023.

Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the fourth quarter and full year ended December 31, 2022.

Leap Therapeutics, Inc. (Nasdaq:LPTX) today announced that BeiGene’s option under the Exclusive Option and License Agreement between Leap and BeiGene granting rights in certain Asian territories to DKN-01, Leap’s anti-DKK1 monoclonal antibody, has expired in accordance with the terms of the agreement.

BioLife Solutions, Inc. (Nasdaq: BLFS) (“BioLife” or the “Company”) today announced financial results for the fourth quarter and year ended December 31, 2022.

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States Food and Drug Administration (FDA) has approved a supplementary New Drug Application (sNDA) for Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) to enable its use for the selection of patients with metastatic prostate cancer, for whom 177Lu 177 PSMA-directed therapy is indicated.